India’s New Drugs Department To Be Headed By Price Chairman
This article was originally published in PharmAsia News
Soon after it was established, India's new Department of Pharmaceuticals named Ashok Kumar, chairman of the Pharmaceutical Pricing Authority, as its first secretary. The NPPA is to remain separate from the new department, which otherwise is to handle policy issues relative to the drug-making industry. The government had not yet named an NPPA replacement for Kumar, its longest-serving chairman. The drugs department is charged with oversight of the infrastructure, manpower and skills for the drug sector as well as promoting public-private efforts in related areas. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.